Sankyo Co. Newsletter
-
Daiichi Sankyo & AstraZeneca's datopotamab deruxtecan recommended for approval in EU to treat patients with previously treated metastatic HR positive, HER2 negative breast cancer
03 Feb 2025 10:20 GMT
… and commercialized by Daiichi Sankyo and AstraZeneca.
The Committee … various settings.
Daiichi Sankyo and AstraZeneca entered into … datopotamab deruxtecan.
The Daiichi Sankyo ADC portfolio consists of … by Daiichi Sankyo.
The second Daiichi Sankyo ADC platform …
-
Daiichi Sankyo Appoints Chief Executive Officer
31 Jan 2025 20:07 GMT
… Manabe’s leadership, Daiichi Sankyo’s pioneering science and … its management structure, Daiichi Sankyo’s Board of Directors … during his tenure at Daiichi Sankyo. Mr. Okuzawa graduated … strong leadership, propelling Daiichi Sankyo to the forefront of …
-
Daiichi Sankyo taps new CEO, aims to build up ADC franchise
31 Jan 2025 16:26 GMT
Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, …
-
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
31 Jan 2025 14:58 GMT
… 50,741 shares in Daiichi Sankyo.
Access the most comprehensive … the next CEO of Daiichi Sankyo and will follow Sunao … will continue to leverage Daiichi Sankyo’s strengths in science … .
Before this development, Daiichi Sankyo and AstraZeneca’s ADC Enhertu …
-
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
31 Jan 2025 04:22 GMT
… its management structure, Daiichi Sankyo’s Board of Directors … his tenure at Daiichi Sankyo. Mr. Okuzawa graduated … strong leadership, propelling Daiichi Sankyo to the forefront of … worldwide.”
About Daiichi Sankyo
Daiichi Sankyo is an innovative global …
-
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer
31 Jan 2025 04:17 GMT
… strengthen its management structure, Daiichi Sankyo’s Board of Directors appointed … life worldwide.”
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare … HEALTH ONCOLOGY CARDIOLOGY
SOURCE: Daiichi Sankyo Company, Ltd
Copyright Business Wire …
-
AstraZeneca, Daiichi Sankyo bring Enhertu to HER2-ultralow setting
28 Jan 2025 20:46 GMT
-
Report says AZ's UK plant decision is not just about funding
03 Feb 2025 18:20 GMT
… use of AZ and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan …
-
AstraZeneca Blames 'Toxic' Climate As It Walks Away from Over $550 Million UK Vaccine Plant
03 Feb 2025 17:19 GMT
… Read: FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain …
-
Lipid Nanoparticle Raw Materials Market to Reach USD 378.13 Million by 2032, Driven by Advances in Drug Delivery
03 Feb 2025 12:39 GMT
… (RNA therapeutics, LNP formulations)
• Daiichi Sankyo - (Nanoparticle drug delivery, Innovative …
About
© 1995-2025